Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in District of Columbia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 195 | 24% |
| 2020 | 0 | 5 | 26% |
| 2021 | 1 | 19 | 30% |
| 2022 | 0 | 6 | 33% |
| 2023 | 2 | 118 | 37% |
| 2024 | 3 | 175 | 39% |
| 2025 from claims | – | 172 139–202 | 41% |
| 2026 forecast | – | 188 148–237 | 40% |
| 2027 forecast | – | 205 152–270 | 41% |
| 2028 forecast | – | 222 157–307 | 42% |
| 2029 forecast | – | 241 164–346 | 42% |
| 2030 forecast | – | 262 171–388 | 43% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in District of Columbia; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 49% hospital outpatient, 51% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 83 | 6,824−3.6%/yr | −3.6%/yr | 3.2 | 80% | 7,210 in 2030+0.9%/yr |
| Florida | 76 | 6,413−2.9%/yr | −2.9%/yr | 2.9 | 87% | 6,520 in 2030+0.3%/yr |
| Tennessee | 36 | 2,272−2.5%/yr | −2.5%/yr | 3.3 | 77% | 2,320 in 2030+0.3%/yr |
| North Carolina | 33 | 2,261−4%/yr | −4%/yr | 2.3 | 36% | 2,170 in 2030−0.7%/yr |
| Maryland | 30 | 2,121−7.2%/yr | −7.2%/yr | 2.4 | 26% | 2,290 in 2030+1.3%/yr |
| Virginia | 28 | 1,985−3.8%/yr | −3.8%/yr | 1.9 | 77% | 2,080 in 2030+0.8%/yr |
| South Carolina | 22 | 1,644−1.1%/yr | −1.1%/yr | 2.4 | 69% | 1,760 in 2030+1.1%/yr |
| Georgia | 19 | 1,497−3.1%/yr | −3.1%/yr | 1.8 | 88% | 1,580 in 2030+0.9%/yr |
| Alabama | 18 | 1,215−6.6%/yr | −6.6%/yr | 2.8 | 45% | 1,170 in 2030−0.7%/yr |
| Louisiana | 14 | 1,034−4.5%/yr | −4.5%/yr | 2.6 | 72% | 980 in 2030−1%/yr |
| Oklahoma | 14 | 1,019−4.8%/yr | −4.8%/yr | 2.1 | 77% | 1,020 in 2030+0.1%/yr |
| Mississippi | 11 | 1,000−1.3%/yr | −1.3%/yr | 2.7 | 72% | 1,010 in 2030+0.2%/yr |
| Kentucky | 16 | 944−6.8%/yr | −6.8%/yr | 2.1 | 85% | 910 in 2030−0.5%/yr |
| Arkansas | 10 | 687−6.8%/yr | −6.8%/yr | 1.8 | 0% | 580 in 2030−2.7%/yr |
| West Virginia | 4 | 208−16%/yr | −16%/yr | 1.0 | 73% | 310 in 2030+6.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 29 | 3,191+3%/yr | +3%/yr | 50.10.9× | 95% | 4,020 in 2030+3.9%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in District of Columbia · Every state · Compare with Texas
Alcon leads with 45% of company spending on these surgeons in 2025, +35 pts on 2024.
In 2025, 7 companies reported engagement with District of Columbia’s surgeons worth $9,613 in consulting, speaking, meals and travel tied to these products, about $3,204 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.